Phreesia (NYSE:PHR) Insider Sells $50,401.20 in Stock

Key Points

• Insider David Linetsky sold 2,165 shares of Phreesia stock for $50,401.20, representing a 1.22% decrease in his ownership of the company.
• Phreesia reported a 14.9% increase in revenue year-over-year, with quarterly earnings surpassing analyst expectations at $0.01 EPS.
• Institutional investors continue to show interest in Phreesia, with 92.10% of the stock currently owned by such investors, indicating strong institutional confidence.

Phreesia, Inc. (NYSE:PHR - Get Free Report) insider David Linetsky sold 2,165 shares of the business's stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $23.28, for a total transaction of $50,401.20. Following the completion of the sale, the insider directly owned 174,952 shares in the company, valued at $4,072,882.56. This represents a 1.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

David Linetsky also recently made the following trade(s):

• On Wednesday, September 17th, David Linetsky sold 1,064 shares of Phreesia stock. The shares were sold at an average price of $23.50, for a total value of $25,004.00.
• On Friday, August 22nd, David Linetsky sold 17,445 shares of Phreesia stock. The stock was sold at an average price of $29.73, for a total transaction of $518,639.85.
• On Monday, August 18th, David Linetsky sold 78 shares of Phreesia stock. The stock was sold at an average price of $29.16, for a total transaction of $2,274.48.
• On Thursday, July 17th, David Linetsky sold 2,063 shares of Phreesia stock. The shares were sold at an average price of $26.89, for a total transaction of $55,474.07.
• On Friday, June 27th, David Linetsky sold 23,729 shares of Phreesia stock. The stock was sold at an average price of $28.50, for a total transaction of $676,276.50.

Phreesia Price Performance

PHR traded up $1.00 on Thursday, hitting $24.28. 801,987 shares of the company were exchanged, compared to its average volume of 1,182,744. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.12 and a current ratio of 2.12. The stock's fifty day moving average is $27.71 and its 200-day moving average is $26.40. Phreesia, Inc. has a 12 month low of $17.07 and a 12 month high of $32.76.

Phreesia (NYSE:PHR - Get Free Report) last announced its quarterly earnings results on Thursday, September 4th. The company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.08. Phreesia had a negative net margin of 5.35% and a negative return on equity of 8.75%. The firm had revenue of $117.26 million during the quarter, compared to analysts' expectations of $116.39 million. During the same quarter last year, the company posted ($0.03) earnings per share. The company's revenue for the quarter was up 14.9% compared to the same quarter last year. Phreesia has set its FY 2026 guidance at EPS. As a group, research analysts forecast that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in PHR. Vanguard Group Inc. grew its holdings in shares of Phreesia by 2.4% during the 1st quarter. Vanguard Group Inc. now owns 4,936,515 shares of the company's stock valued at $126,177,000 after purchasing an additional 113,405 shares during the last quarter. Greenhouse Funds LLLP boosted its position in Phreesia by 12.5% in the second quarter. Greenhouse Funds LLLP now owns 3,325,262 shares of the company's stock valued at $94,637,000 after buying an additional 368,352 shares in the last quarter. Champlain Investment Partners LLC grew its stake in shares of Phreesia by 20.0% during the first quarter. Champlain Investment Partners LLC now owns 2,946,489 shares of the company's stock worth $75,312,000 after buying an additional 490,340 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Phreesia by 108.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,644,988 shares of the company's stock worth $67,606,000 after buying an additional 1,377,904 shares in the last quarter. Finally, Franklin Resources Inc. lifted its stake in shares of Phreesia by 0.6% in the 2nd quarter. Franklin Resources Inc. now owns 1,524,251 shares of the company's stock valued at $43,380,000 after acquiring an additional 9,057 shares during the last quarter. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

PHR has been the topic of several research reports. Truist Financial upped their price target on shares of Phreesia from $35.00 to $36.00 and gave the company a "buy" rating in a research note on Friday, September 5th. Stephens reissued an "overweight" rating and issued a $32.00 price objective on shares of Phreesia in a report on Wednesday, September 3rd. KeyCorp raised their target price on shares of Phreesia from $28.00 to $35.00 and gave the stock an "overweight" rating in a report on Monday, July 14th. Raymond James Financial set a $33.00 price target on shares of Phreesia and gave the company an "outperform" rating in a research report on Friday, September 5th. Finally, DA Davidson raised Phreesia to a "strong-buy" rating in a research report on Monday, September 8th. One analyst has rated the stock with a Strong Buy rating and twelve have assigned a Buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $34.08.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.